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http://dx.doi.org/10.1016/j.ccr.2013.04.011SUMMARYThe EZH2 histone methyltransferase is highly expressed in germinal center (GC) B cells and targeted by so-
maticmutations inBcell lymphomas.Here,wefind thatEZH2deletionorpharmacologic inhibition suppresses
GC formation and functions. EZH2 represses proliferation checkpoint genes and helps establish bivalent
chromatin domains at key regulatory loci to transiently suppress GC B cell differentiation. Somatic mutations
reinforce these physiological effects through enhanced silencing of EZH2 targets. Conditional expression of
mutant EZH2 in mice induces GC hyperplasia and accelerated lymphomagenesis in cooperation with BCL2.
GC B cell (GCB)-type diffuse large B cell lymphomas (DLBCLs) are mostly addicted to EZH2 but not the more
differentiated activated B cell (ABC)-type DLBCLs, thus clarifying the therapeutic scope of EZH2 targeting.INTRODUCTION
Themajority of B cell lymphomas arise from germinal center (GC)
B cells, which form part of the humoral immune response toSignificance
We show that EZH2 is required for the humoral immune respon
chromatin domains at genes required for exit of B cells from th
toward increased lysine 27 residue of histone 3methylation, lea
as differentiation blockade, GC hyperplasia, and accelerated
mutant EZH2 functions are essential for GCB-type DLBCLs bu
tion of EZH2 and its mutants in mature B cells and lymphomas
geted therapy for GCB-type DLBCLs.T cell-dependent antigen stimulation (Ci et al., 2008; Klein and
Dalla-Favera, 2008). GC B cells originate frommature, VDJ rear-
ranged, antigen-naive B cells present in lymphoid follicles that,
upon activation, migrate to the center of lymphoid follicles andse. EZH2 function is linked to de novo formation of bivalent
e GC. Mutant EZH2 alleles tip the balance of these domains
ding tomore potent and permanent silencing. Thismanifests
lymphomagenesis in cooperation with BCL2. Wild-type and
t dispensable for ABC-DLBCLs. These data reveal the func-
and provide the basis for specific rational combinatorial tar-
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Role of EZH2 in B Cell Lymphomasform GCs. GC B cells are unique in their ability to replicate at an
accelerated rate while undergoing somatic hypermutation,
which requires attenuation of DNA damage sensing and replica-
tion checkpoints. Clonal expansion of these cells is followed by
terminal differentiation of the subset of B cells that encode high
affinity antibodies; by contrast, the remainder of GC B cells
undergoes apoptosis. The rapid proliferation of GC cells with
concomitant attenuation of DNA damage responses increases
the risk of oncogenicmutations as a byproduct of somatic hyper-
mutation and class switch recombination. Such mutations can
lead to the development of diffuse large B cell lymphoma
(DLBCL) and follicular lymphoma (FL) (Alizadeh et al., 2000; Klein
and Dalla-Favera, 2008). Understanding how B cells impose and
maintain the GC phenotype may thus provide important clues
that could explain the pathogenesis of GC B cell-derived lym-
phomas and inform the design of rational therapeutic strategies
for patients with DLBCL and FL.
Upon activation, GC B cells upregulate and highly express
EZH2, a SET domain containing histone methyltransferase that
forms part of polycomb repressive complex-2 (PRC2) (Raa-
phorst et al., 2000; Velichutina et al., 2010). EZH2 catalyzes
methylation of the lysine 27 residue of histone 3 (H3K27) but is
mostly catalytically active when complexed with the PRC2 com-
ponents EED and SUZ12 (Chase and Cross, 2011; Mahmoudi
and Verrijzer, 2001). H3K27 methylation is a repressive histone
mark associated with gene repression (Cao et al., 2002; Czermin
et al., 2002; Mu¨ller et al., 2002). EZH2 is critical for normal devel-
opment, and EZH2 knockout embryos fail to implant and
undergo gastrulation (O’Carroll et al., 2001). EZH2 plays a major
role in regulating gene expression patterning in embryonic and
tissue-specific stem cells, where it contributes to setting genes
into a ‘‘poised’’ bivalent state characterized by the simultaneous
appearance of the H3K27me3 repressive mark along with the
H3K4me3 activation-associated mark (Bernstein et al., 2006;
Shin et al., 2012). These poised bivalent genes can then be
resolved into activated or stably repressed loci, depending on
lineage commitment. In tissue-specific stem cells, EZH2 and
partner proteins are critical for the proper coordination of differ-
entiation and proliferation. For example, conditional knockout
studies in early stages of B cell differentiation showed that
EZH2 is important for normal immunoglobulin VDJ recombina-
tion in pre-B cells (Su et al., 2003). However, after the pre-B
cell stage, EZH2 expression declines and is not detectable in
mature B cells located within lymphoid tissues until these cells
enter the GC reaction (Su et al., 2003; van Galen et al., 2004;
Velichutina et al., 2010). Once B cells exit the GC reaction,
EZH2 is once again downregulated (Velichutina et al., 2010).
We previously found that EZH2 target genes in GC B cells only
partially overlap with EZH2 targets in embryonic stem cells, sug-
gesting that it hasGC-specific functions (Velichutina et al., 2010).
Moreover, PRC2 components, including EZH2, are often highly
expressed in GC B cell-derived DLBCL (van Kemenade et al.,Figure 1. EZH2 Is Required for Germinal Center Formation
(A–C) EZH2fl/fl, EZH2/, andWTC57BL6 control mice (n = 5 per group) were imm
with SRBC and treated with GSK503 (150 mg/kg/day) or vehicle (n = 5 per gr
quantification. (B and E) Splenic tissue was stained with PNA, EZH2, Ki67, and B2
Values in (A), (C), (D), and (F) are shown as mean ± SEM. t test, *p < 0.05, **p < 0
See also Figure S1 and Tables S1–S4.2001), suggesting that PRC2 functions may contribute to line-
age-based proliferation of malignant B cells. RNA-sequencing
studies recently identified heterozygous somatic point mutations
targeting the EZH2 SET domain, most commonly affecting the
Y641 residue of EZH2, in 30% of GC B cell (GCB)-type DLBCL
and 10% of FL (Morin et al., 2010). These mutations alter the
enzymatic activity of EZH2, resulting in a protein that fails to
recognize unmodified H3K27 and preferentially converts
mono- or dimethylated H3K27 to the trimethylated state (Sneer-
inger et al., 2010; Yap et al., 2011). DLBCL cell lines harboring
EZH2 point mutations display aberrant accumulation of
H3K27me3 compared to wild type (WT)-EZH2 cells (McCabe
et al., 2012a; Sneeringer et al., 2010). The importance of EZH2
in maintaining the growth of lymphoma cells was demonstrated
in small interfering RNA knockdown experiments (Velichutina
et al., 2010) andmore recently through the development of highly
specific and potent EZH2 small molecule inhibitors (Knutson
et al., 2012; McCabe et al., 2012b; Qi et al., 2012). However,
the role and requirement for EZH2 and its mutant alleles in the
formation of GCs and pathogenesis of B cell lymphomas has
not been explored, nor is itsmechanism of transformation known
beyond the association with global cellular abundance of
H3K27me3. Here, we explore the function of normal and mutant
EZH2 inmature B cells and lymphomas usingmurinemodels and
human cells. We also address the mechanisms of action of
WT and mutant EZH2 and provide the basis for rational, combi-
natorial, targeted therapy for GCB-type DLBCL.
RESULTS
EZH2 Is Required for Formation of Germinal Centers
The increased expression of EZH2 in GC B cells suggested that
this protein plays critical roles in mediating the phenotype of GC
B cells. However, EZH2 deletion is lethal in early embryonic
development (O’Carroll et al., 2001), and its inducible knockout
in early hematopoietic cells perturbs lymphoid differentiation at
the pre-B cell stage (Su et al., 2003). We therefore crossed con-
ditional Ezh2/ mice with the Cg1cre strain, which expresses
cre recombinase in GC B cells (Casola et al., 2006). Upon reach-
ing immunological maturity, Ezh2fl/fl, Ezh2/, and WT control
mice were injected with T cell-dependent antigen sheep red
blood cells (SRBC) to induce GC formation and sacrificed
10 days later, at which time the GC reaction is at its peak.
EZH2 loss resulted in a marked reduction in the number of
splenic GC (GL7+/FAS+/B220+) B cells (Figure 1A). Immunohisto-
chemical analysis using peanut agglutinin (a GC B cell marker)
revealed a reduction in the number (p < 0.0001) and size
(p = 0.001) of GCs in Ezh2/ versus Ezh2+/+ mice, whereas there
was no change in GCs in Ezh2fl/fl mice (Figures 1B and 1C). There
was also marked reduction in Ki67-positive cells consistent with
loss of the proliferative GC B cell compartment (Figure 1B). The
histologic appearance of the spleen and primary lymphoidunizedwith SRBC to induce GC formation. (D–F) C57BL6mice were immunized
oup). (A and D) Representative flow cytometric plot of splenic GC cells and
20. (C and F) Quantitative imaging of PNA staining from (B) and (E), respectively.
.01, ***p < 0.001.
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Figure 2. Mutant EZH2 Induces Germinal
Center Hyperplasia
EZH2fl/fl and EZH2Y641Nmicewere immunizedwith
NP-KLH and treated with GSK503 (150 mg/kg/
day) or vehicle (n = 6 per group).
(A) Representative flow cytometric plot of splenic
GC cells and quantification.
(B) Splenic tissue was stained with PNA, EZH2,
Ki67, and B220.
(C) Quantitative imaging of PNA from (B).
(D) Immunoblotting from whole cell lysates from
sorted splenic GC B cells (GL7+/FAS+/B220+).
Values in (A), (C), and (D) are shown as mean ±
SEM. t test, **p < 0.01, ***p < 0.001.
See also Figure S2.
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Role of EZH2 in B Cell Lymphomasfollicles was otherwise normal (Figure S1A available online), and
marginal zone and follicular B cells were unaffected (Figure S1B).
The few residual GC B cells were EZH2 positive, consistent with
incomplete cre-mediated excision of Ezh2 and the notion that
GC B cells require EZH2 (data not shown). A similar phenotype
was observed when Ezh2/ mice were injected with nitro-
phenyl-keyhole limpet hemocyanin (NP-KLH), which induces
cognate high affinity antibodies (Figure S1C). The defect in GC
formation was accompanied by impaired immunoglobulin affin-
ity maturation with reduction in formation of high-affinity anti-
bodies (Figure S1D).
We next immunized a cohort of C57BL6 mice with SRBC fol-
lowed by once daily treatment with 150 mg/kg/day GSK503, a
specific EZH2 methyltransferase inhibitor or vehicle. GSK503
was designed by performing high-throughput screening for
EZH2 methyltransferase-inhibiting compounds followed by
chemical optimization (Figure S1E). GSK503 inhibits the methyl-
transferase activity of WT and mutant EZH2 with similar potency
(Ki
app = 3–27 nM) and is structurally related to GSK126 and
GSK343 (McCabe et al., 2012b; Verma et al., 2012). GSK503680 Cancer Cell 23, 677–692, May 13, 2013 ª2013 Elsevier Inc.was >200-fold selective over EZH1
(Ki
app = 636 nM) and >4,000-fold selective
over other histone methyltransferases
(Tables S1–S4; Figures S1F and S1G).
GSK503 displayed favorable pharmaco-
kinetics in mice (Figures S1H and S1I)
and was thus selected for use in in vivo
experiments. We assessed the effects of
GSK503-mediated EZH2 inhibition in vivo
in GC B cells. GSK503 but not vehicle
prevented the formation of GC after
SRBC or NP-KLH immunization, pheno-
copying the Ezh2 null phenotype.
GSK503 treatment led to reduced
numbers of GC B cells by flow cytometry,
reduced number and volume of GCs by
immunohistochemistry, and impaired for-
mation of high-affinity antibodies (Fig-
ures 1D–1F, S1J, and S1K). There was
no effect on marginal zone or follicular
B cells (Figure S1L). Immunoblot analysis
revealed that GSK503 reduced the level
of H3K27me3 in splenocytes, confirminginhibition of the catalytic function of EZH2 in vivo (Figure S1M).
Collectively, these data demonstrate that EZH2 is required for
the formation of GCs and immunoglobulin affinity maturation
and that this function is dependent on its histone methyltransfer-
ase activity.
Mutant EZH2 Induces Germinal Center Hyperplasia
Given that EZH2was essential for development of GCB cells, we
surmised that gain of function EZH2 mutants might reinforce
these actions, with implications for lymphomagenesis. To
address this point, we generated mice conditionally expressing
the Ezh2Y641N lymphoma allele from the ColA1 locus after exci-
sion of a lox-stop-lox cassette (Figures S2A–S2C). These
animals were crossed into the Cg1cre background to express
Ezh2Y641N in GC B cells. Subsequent to immunization, these
mice displayed greatly increased numbers of GL7+/FAS+/
B220+ GC B cells (p < 0.001; Figure 2A) and increased number
and size of GCs (p < 0.0005; Figures 2B and 2C), while cre-nega-
tive Ezh2fl/fl animals showed no such effects. There was no effect
on marginal zone or follicular B cell numbers or morphology
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increase in the abundance of H3K27me3 in sorted GC B cells
from Ezh2Y641N versus nonrecombined mice (p < 0.005; Fig-
ure 2D), analogous to what is observed in mutant EZH2 DLBCL
cell lines (McCabe et al., 2012a; Sneeringer et al., 2010).
Lymphoid GC hyperplasia was dependent on the increased his-
tone methyltransferase activity as GSK503 treatment abrogated
the Ezh2Y641N GC hyperplasia phenotype (p < 0.001; Figures
2A–2C). These data demonstrate that Y641 mutation reinforces
the GC phenotype-driving function of wild-type EZH2, resulting
in an expansion of these proliferative and mutagenic cells. How-
ever, Ezh2Y641N knockin mice did not develop B cell lymphomas
(data not shown).
Mutant EZH2 Enhances Proliferation Effects in Part
through Greater Repression of CDKN1A
To characterize in more detail the functions of EZH2 in mature
B cells, we next expressed wild-type EZH2 and EZH2Y641 in mu-
rine BCL1 cells. BCL1 cells originate from a spontaneous murine
lymphoproliferative disease, exhibit clonal somatic hypermuta-
tion, and have been used to model GC B cell biology (Blackman
et al., 1986). BCL1 cells were transduced with GFP-expressing
retrovirus harboring FLAG-tagged Ezh2Y641N, Ezh2Y641F, or WT
Ezh2 (Figure 3A). BCL1 cells transduced with EZH2Y641N and
EZH2Y641F exhibited increased H3K27me3 levels, whereas
H3K27me3 levels were unchanged by WT EZH2 (Figures 3A
and 3B). EZH2Y641N and EZH2Y641F but not WT EZH2 conferred
a significant growth advantage to BCL1 cells compared to vector
infected cells (p < 0.05; Figure 3C). Moreover, EZH2Y641N and
EZH2Y641F induced >10-fold expansion in colony formation as
compared to WT EZH2 or vector (Figure 3D). Treatment with
the specific EZH2 inhibitor GSK343 (Verma et al., 2012; Figures
S1E–S1G) but not vehicle or the inactive chemical control
GSK669 depleted H3K27me3 in BCL1 cells (Figure 3E) and
abrogated colony formation induced by EZH2Y641N or EZH2Y641F
(Figure 3F), confirming that enzymatic activity is required for
their biological effects.
Given that BCL1 cells express endogenous EZH2 already (Fig-
ure 3A) and expression of exogenous EZH2 did not affect prolif-
eration or colony formation in BCL1 cells, the effects we
observed were specific to expression of mutant EZH2 in
lymphoid cells. Recent studies have shown that EZH2 inhibitors
and RNA interference suppress proliferation of EZH2 mutant
DLBCL cells (Knutson et al., 2012; McCabe et al., 2012b; Qi
et al., 2012; Velichutina et al., 2010). Consistent with these find-
ings, small hairpin RNA (shRNA) depletion of EZH2 protein (Fig-
ure 3G) in EZH2 mutant Pfeiffer and WSU-DLCL2 cell lines led
to >50% suppression of cell growth relative to shRNA control.
shRNA-mediated depletion of EZH2 in WT EZH2 Farage cells
led to a more modest and delayed 20%–40% decrease of
growth (Figure 3H). GSK343 2 mM even more efficiently depleted
H3K27me3 and more rapidly suppressed the growth of DLBCL
cell lines, with greater effect observed in those with mutant
EZH2 (Figures S3A and S3B). We identified CDKN1A as a direct
EZH2 target in GC B cells and DLBCL (Velichutina et al., 2010;
data not shown). Treatment of WT EZH2 cells with GSK343 led
to a 2–4-fold induction of CDKN1A, while in mutant cell lines
EZH2 inhibition led to 8–12-fold activation (Figure 3I). While
EZH2 shRNA or GSK343 targeting of EZH2 led to a reductionin DLBCL cell viability, shRNA-mediated depletion of CDKN1A
partially rescued this phenotype (p < 0.05; Figures 3J, 3K, and
S3C). We performed gene expression profiling in diagnostic
samples from patients with DLBCL and observed a trend for
CDKN1A to be expressed at a lower level in GCB-DLBCL
patients harboring EZH2 mutations versus GCB-DLBCL with
wild-type EZH2 (p = 0.07; Figure S3D). These data are consistent
with the notion that mutant EZH2 reinforces repression of GC B
cell EZH2 target genes and that CDKN1A silencing may
contribute, along with other genes, to the phenotypic effects of
EZH2 in B cells.
EZH2Mediates Differentiation Blockade in DLBCL Cells
GCB-DLBCLs exhibit differentiation blockade, locking them into
the GC phenotype (Rui et al., 2011). Given that gain-of-function
mutants induce an expansion in the population of GC B cells,
we postulated that EZH2 might play a critical role in suppressing
differentiation. We first compared RNA sequencing (RNA-seq)
gene expression profiles in BCL1 cells transduced with WT or
mutant EZH2. This analysis revealed that, in BCL1 cells,
EZH2Y641N or EZH2Y641F increased repression of genes that
are normally expressed upon terminal differentiation into plasma
andmemory cells when compared to EZH2-WT-expressing cells
(gene set enrichment analysis [GSEA] false discovery rate [FDR]
q < 0.009; Figure 4A). We induced differentiation in BCL1 cells
using interleukin-2 (IL-2) and IL-5. These cytokines typically drive
BCL1 cells toward a partial plasma cell phenotype accompanied
by proliferation arrest (Blackman et al., 1986). Expression of
EZH2Y641N or EZH2Y641F but not WT-EZH2 significantly impaired
cytokine-induced proliferation arrest (p < 0.05; Figure 4B) and
more profoundly suppressed activation of Prdm1, a key plasma
cell differentiation gene (p < 0.01; Figure 4C).
Based on these data, we next examined whether EZH2 inhibi-
tion by GSK343 induces differentiation in human DLBCL cells. In
GCB-type DLBCL cell lines (two mutant and one WT), EZH2
inhibitor treatment induced upregulation of the plasma cell
proteins syndecan/CD138 and p63, upregulation of the memory
cell marker CD27, and downregulation of the B cell surface
marker CD20 (Figure S4A). Treatment with GSK343 but not
GSK669 induced functional evidence of differentiation mani-
fested by increased light chain and immunoglobulin production
(Figure 4D) and morphologic changes consistent with plasma
cell differentiation (Figure 4E). Gene expression analysis by
quantitative PCR revealed upregulation of differentiation-related
genes, includingPRDM1, IRF4, and syndecanCD138 (Figure 4F),
with greater effect generally noted in EZH2 mutant DLBCL cells
(p < 0.05). Analysis of RNA-seq expression profiles induced by
GSK343 in three DLBCL cell lines (two mutant and one WT
EZH2) showed enrichment for transcriptional programs involved
in plasma and memory B cell differentiation (FDR q < 0.001; Fig-
ure S4B). We also found strong enrichment in gene sets involved
in exit from the GC reaction, including genes induced by CD40,
interferon regulatory factor 4 (IRF4), IL10, and nuclear factor
kB (NF-kB), and, notably, the activated B cell (ABC)-DLBCL
signature (which consists of activation of these post-GC genes),
as well as genes involved in apoptosis and immune responses
(Figure 4G). Memory and plasma cell differentiation genes
were among genes preferentially repressed in GCB-type DLBCL
patients with EZH2 mutations as compared to GCB-DLBCLCancer Cell 23, 677–692, May 13, 2013 ª2013 Elsevier Inc. 681
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Figure 3. Mutant EZH2 Enhances Proliferation Effects through Repression of CDKN1A
(A) Immunoblotting from nuclear extracts from GFP+ BCL1 cells expressing GFP-FLAG-tagged EZH2Y641F, EZH2Y641N, or WT EZH2.
(B) Mass spectrometry measurement of H3K27me3 mark.
(C) Viability using trypan blue exclusion.
(D) Colony counts and representative pictures of transduced BCL1 cells.
(E) Immunoblotting was performed as in (A) with cells treated as indicated for 3 days.
(F) Colony counts and representative pictures of transduced BCL1 cells treated with 2.5 mM GSK669 or GSK343.
(G) Immunoblotting from whole cell lysates from yellow fluorescent protein (YFP)+ DLBCL cells expressing two independent EZH2 shRNAs or control.
(H) Viability of DLBCL YFP+ by flow cytometry using annexinV and DAPI exclusion. Green, WT EZH2; blue, mutant EZH2 cell lines.
(legend continued on next page)
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S6). IRF4 was expressed at a significantly lower level in EZH2
mutant versus WT GCB-DLBCL patients (p = 0.01; Figure S4C).
Collectively, these data suggest that EZH2 maintains the GC
phenotype by suppressing transcriptional programs required
for exiting the GC reaction and terminal differentiation. Mutant
EZH2 augments these same functions by reinforcing repression
of B cell differentiation genes.
Mutant EZH2 Aberrantly Represses Genes through
Increased Promoter H3K27 Trimethylation
In order to gain insight into how mutant EZH2 might reinforce or
alter normal EZH2-dependent transcriptional programs, we per-
formed H3K27me3 chromatin immunoprecipitation sequencing
(ChIP-seq) in BCL1 cells after transduction with EZH2Y641N,
EZH2Y641F, WT EZH2, or vector and determined how gene
expression in these cells responded to EZH2 inhibitors. Cells
transduced with either EZH2Y641N or EZH2Y641F showed a
marked increase in the abundance of H3K27me3 at gene pro-
moters compared to EZH2 WT-transduced cells (p < 2 3 1016
for both mutants; Figure 5A), and genes with abundant
H3K27me3 were generally repressed (p < 2 3 1016; data not
shown). In addition, loci displaying increased H3K27me3 were
more potently induced upon exposure of the BCL1-
EZH2Y641N/EZH2Y641F cells to GSK343 than EZH2 WT cells
(p < 5 3 1011 for EZH2Y641N and EZH2Y641F; Figure 5B).
Remarkably, those genes with increased H3K27me3 due
to mutant EZH2 and more strongly induced by GSK343
corresponded to the set of human EZH2 target genes that
acquire de novo H3K27me3 in human GC B cells (FDR
q < 0.001; Figure 5C). Hence, mutant EZH2 appears to func-
tion at least in part by exaggerating the epigenetic silencing
of normal GC B cell targets of wild-type EZH2.
EZH2 Is Linked to Formation of GC B Cell-Specific
Bivalent Genes Involved in Differentiation
In stem cells, a subset of genes that are H3K27 trimethylated by
EZH2 are also marked by the activating chromatin modification
H3K4me3. These so-called ‘‘bivalent (H3K4me3/H3K27me3)
domains’’ are believed to represent a mechanism for poising
key lineage transcription factors so that they can be either acti-
vated or repressed during subsequent differentiation (Bernstein
et al., 2006). We examined H3K27me3 and H3K4me3 distribu-
tion in purified primary human naive B (NB) cells and GC B cells
by ChIP-seq. Notably, even though GC B cells are mature,
committed cells (i.e., in contrast to stem cells), we find that
they gain 1,026 new bivalent domains at promoters that are
not found in NB cells (Figure 5D). Of these 910 (88%), bivalent
promoters originate from H3K4me3-only promoters in NB cells
(Figure 5D), indicating that most bivalent loci in GC B cells occur
due to acquisition of H3K27me3, concordant with upregulation
of EZH2 in these cells. ChIP-seq profiles from seven human
GCB-DLBCL cell lines showed that these bivalent promoters(I) qRT-PCR of CDKN1A in DLBCL cell lines treated with 2 mM GSK for 7 days. G
(J) Pfeiffer cells were cotransduced with the indicated shRNAs and viable YFP+
(K) Pfeiffer cells expressing two independent shCDKN1As or control were treate
Values in (B)–(D), (F), and (H)–(K) are mean of duplicate or triplicate ± SD. t test,
See also Figure S3.were preferentially bound by EZH2 (p < 1 3 1016; Figure 5E).
In primary human GC B cells, bivalent genes were expressed
at lower levels than loci with H3K4me3 alone but at higher levels
than genes marked only by H3K27me3 (p < 1 3 10300; Fig-
ure 5F). This is consistent with the proposed poised nature of
bivalent genes in stem cells. GCB cell bivalent genes were highly
enriched in gene sets associated with termination of the GC
reaction, such as IRF4-induced, ABC-DLBCL,memory cell upre-
gulated genes, as well as other GCB cell relevant genes, such as
negative regulation of cell cycle (Figure S5A). The key regulatory
transcription factors IRF4 and PRDM1 were among the GC
B cell-specific bivalent genes, consistent with the notion that
these genes are marked for dynamic activation upon exit from
theGC reaction (Figure S5B) and that bivalentmarks at this stage
of B cell maturation function to transiently suppress terminal
differentiation.
We wondered whether somatic mutation of EZH2 might lock
these bivalent promoters into a more repressed configuration,
perhaps helping to explain the irreversible differentiation
blockade induced by mutant EZH2. Indeed, we observed that
GC B cell bivalent genes were even more highly repressed in
murine BCL1 cells transduced with EZH2Y641N and EZH2Y641F
than in WT EZH2-transduced cells (FDR q < 0.001; Figure 5G).
GC B cell bivalent domain genes were also significantly more
repressed in human GCB-DLBCL patients with EZH2 somatic
mutations compared to GCB-DLBCL with WT EZH2 (FDR
q < 0.001; Wilcoxon p < 0.0006; Figures 5H and 5I). GC B cell
bivalent genes involved in GC B cell differentiation, such
as IRF4-induced genes, CD40-induced genes, and plasma/
memory cell genes, were especially enriched among genes
differentially expressed in mutant EZH2 DLBCL patients versus
GCB-DLBCL specimens with wild-type EZH2 (Figures S5C and
S5D). GC B cell bivalent genes were also significantly enriched
among genes induced by GSK343 treatment of individual human
DLBCL cell lines (FDR q < 0.001; Figure S5E; hypergeometric
distribution test, p = 3.43 1048). ChIP-seq showed enrichment
of H3K27me3 at GCB bivalent genes in DLCBL cell lines (p < 23
1016; data not shown). To confirm that bivalent marks are
indeed occurring at the same chromatin regions within GC-
derived DLBCL cells, we performed ChIP re-ChIP assays. The
key regulatory transcription factors necessary for GC exit,
IRF4, and PRDM1, as well as the proliferation checkpoint gene
promoter CDKN1B, all shown to be putative GC B cell bivalent
genes by our ChIP-seq experiments, were confirmed to be
significantly co-occupied by H3K27me3 and H3K4me3 marks
(Figure S5F). In contrast, HOXA7 (which is silenced in mature B
cells) was exclusively H3K27 trimethylated and BCL6 (which is
highly expressed in GC B cells) was almost exclusively H3K4 tri-
methylated. Collectively, these data suggest that, in normal GC
B cell development, EZH2 reversibly suppresses terminal differ-
entiation by forming or maintaining bivalent domains at specific
loci that are also marked by H3K4me3, in addition to epigeneti-
cally silencing other genes through pure H3K27me3. In B cellreen and blue code as in (H).
cells counted as in (H).
d with 2 mM GSK for 6 days, and viability was measured as in (H).
*p < 0.05, **p < 0.01, ***p < 0.001. WT, WT EZH2.
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Figure 4. EZH2 Mediates Differentiation Blockade
(A) GSEA in WT versus mutant EZH2 BCL1-transduced cells. NES, normalized enrichment score.
(B) Cells were treated with 20 ng/ml IL2 and IL5 for 5 days and viability measured using trypan blue exclusion.
(C) qRT-PCR of Prdm1.
(D) Cells were treated with 2 mM GSK343 or control GSK669 for 7 days, and immunoglobulin (Ig) expression levels were examined by flow cytometry.
(E) Representative pictures of cells treated as in (D).
(F) qRT-PCR of indicated mRNAs in cells treated with 2 mM GSK for 7 days. Green, WT EZH2; blue, mutant EZH2 cell lines.
(legend continued on next page)
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perhaps by increasing the frequency with which these genes
are H3K27methylated among tumor cells or by more subtle stoi-
chiometric effects, tipping the balance of H3K27 toward trime-
thylation and away from demethylation.
EZH2 Cooperates with BCL2 to Generate Germinal
Center-Derived Lymphomas
We next investigated whether mutant EZH2 might cooperate
with other GC B cell lymphoma oncoproteins, such as BCL2,
which is frequently translocated in patients with EZH2Y641 muta-
tions (Morin et al., 2011). We transduced bone marrow of vav-
Bcl2 mice with retrovirus expressing GFP and encoding WT
EZH2, EZH2Y641F, or GFP alone and transplanted them into
lethally irradiated cohorts of ten recipients each (Figure 6A).
Animals were immunized with SRBC every 4 weeks to ensure
continuous formation of GCs. Macroscopic examination of
spleens showed marked splenomegaly in EZH2Y641F versus
EZH2 WT or empty vector (Figure 6B). Immunoblot analysis of
splenic extracts showed similar levels of expression of EZH2 in
the EZH2 WT and EZH2Y641F mice (Figure 6C). By contrast,
H3K27me3 abundance was only elevated in splenocytes from
EZH2Y641F mice, whereas H3K27me3 levels in EZH2 WT mice
were similar to controls (Figure 6C). The livers of EZH2Y641F but
not EZH2WTmice were also significantly enlarged versus vector
control (Figure 6D).
Detailed histopathologic examination and determination of
clonality by immunoglobulin gene rearrangements indicated
that, whereas 70% of EZH2Y641F mice developed a B cell lym-
phoma at 111 days, by contrast, only 20% of the WT EZH2
and none of the empty vector (EV) mice showed evidence of lym-
phoma at this time point. All EV and WT EZH2 mice displayed
evidence of follicular hyperplasia, as expected in Bcl2 trans-
genic mice (Figure 6E). However, examination of spleens in
EZH2Y641F/Bcl2 mice revealed disruption of splenic architec-
ture by neoplastic-appearing B220+ B cells, most of which
were EZH2 positive (Figures 6E and S6A). Neoplastic B cells
were large (3 to 4 times the size of reactive lymphocytes) with
pleomorphic nuclear morphology, fine chromatin and several
nucleoli, 60% Ki-67 expression, and were similar morphologi-
cally to human DLBCLs with centroblastic morphology (Figures
S6A and S6B).
EZH2Y641F/Bcl2 mice displayed extensive infiltration of multi-
ple tissues by neoplastic B cells, including lung, liver, lymph no-
des, thymus, pericardiac soft tissue, pancreas, kidneys, salivary
glands, urinary bladder, thyroid, ovarian bursa, bone marrow,
skeletal muscles, small intestine, and stomach (Figures S6C
and S6D; data not shown). Histologic examination of lungs
revealedmarked perivascular and peribronchiolar andmild inter-
stitial infiltration of neoplastic B cells (Figure S6C). In the liver,
infiltration was also extensive, with large periportal and to lesser
extent perivenular and canalicular infiltrates (Figure S6D). Lymph
nodes in EZH2Y641F/Bcl2mice were also infiltrated by neoplastic(G) Heat map of overrepresented gene categories among genes upregulated b
WSU-DLCL2, and Pfeiffer cells. Enrichment measured using hypergeometric p v
(H) GSEA in GCB-DLBCL patient samples with WT versus mutant EZH2. Value
**p < 0.01, ***p < 0.001.
See also Figure S4 and Tables S5 and S6.cells with effacement of normal architecture and a mixture of
nodular and diffuse patterns (data not shown). PCR amplification
of IgVH regions from purified B220+ splenocytes revealed a
dominant band in the background of few very weak bands, sug-
gestive of a mostly monoclonal population of B cells (Figure 6F).
Overall, the histopathological analysis was consistent with an
aggressive DLBCL-like disease.
The two EZH2 WT animals that developed lymphoid malig-
nancy included one with T cell and one with B cell disease and
manifested a more indolent phenotype, including better preser-
vation of the lymphoid architecture, minimal tissue infiltration in
lung and liver, and were composed of plasma cells and reac-
tive-appearing small lymphocytes (data not shown). A second
cohort of Bcl2-transduced mice (EZH2Y641F n = 12, WT
EZH2 n = 8, and GFP alone n = 9) were observed for survival.
EZH2Y641F/Bcl2 manifested an accelerated lethal phenotype,
with deaths due to progressive lymphoma beginning at day 90,
whereas WT and EV mice began to die at day 140 (Figure S6E).
The EZH2Y641F mice displayed a trend toward reduced median
survival (median survival EZH2Y641F: 203 days, WT EZH2: 252,
EV: 243).
Finally, given that BCL2 and EZH2 can cooperate in lympho-
magenesis, we hypothesized that BH3 mimetic drugs, such as
obatoclax and ABT737, which block BCL2 function, might
enhance the activity of EZH2 inhibitors. We exposed a panel of
GCB DLBCL cells to increasing concentrations of GSK343 or
GSK503, in combination with ABT737 or Obatoclax. In almost
every cell line tested, the concentration of GSK343 or GSK503
required to yield 50% growth inhibition was reduced when cells
were concomitantly treated with BH3 mimetics (Figures 6G and
S6F). In order to determine the impact of EZH2 inhibitor combi-
natorial therapy in a preclinical model, we evaluated the action of
GSK503 and Obatoclax alone or in combination in mice bearing
human DLBCL cell line (SUDHL4 and SUDHL6) xenografts.
Although both GSK503 and Obatoclax inhibited tumor growth
alone, the combination of these inhibitors again more potently
and significantly suppressed tumor xenograft growth (Figures
6H and S6G). EZH2 mutants therefore enable, accelerate, and
maintain malignant transformation of GC B cells in cooperation
with BCL2.
EZH2 Targeted Therapy Preferentially Affects GCB
but Not ABC DLBCL Cells
EZH2 gain-of-function somatic mutations are restricted to GCB-
type DLBCLs (Morin et al., 2010). Moreover, whereas EZH2 is a
critical mediator of the GC B cell phenotype, which is reflected
by the phenotype of GCB-DLBCL, it also represses genes and
pathways that drive the phenotype of ABC-DLBCLs (e.g., IRF4
and NF-kB pathway genes). We questioned whether these
GCB-specific functions would translate to a specific role for
EZH2 in the pathogenesis and therapeutic targeting of GCB
versus ABC subtypes of DLBCL. Along these lines, we noted
that EZH2 target genes were significantly more repressed iny EZH2 shRNA or 2 mM GSK343 for 7 days in Ly7, Ly1, SUDHL5, Farage,
alues.
s in (B)–(D) and (F) are mean of duplicate or triplicate ± SD. t test, *p < 0.05,
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Figure 5. Mutant EZH2Aberrantly RepressesGenes by Increasing H3K27me3 at Promoters, and EZH2Generates GCBCell-Specific Bivalent
Genes Involved in Differentiation
(A) ChIP-seq density plot.
(B) Heat map of change in expression of genes with increased H3K27me3 within promoters in BCL1 cells treated with 0.5 mM GSK for 3 days.
(C) GSEA of GCB cell-specific H3K27me3 targets in WT versus mutant EZH2 BCL1 cells.
(D) State of GCB cell bivalent promoters within naive B cells (NBC).
(E) Density strip representations of normalized EZH2 ChIP-seq reads within DLBCL cell line promoters.
(legend continued on next page)
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repressed when comparing ABC versus mutant EZH2 DLBCLs
(Figure 7A). Gene set enrichment analysis revealed that EZH2
target genes (Figures 7B and 7C), including GCB bivalent genes
(Figure S7A) were overrepresented among genes upregulated in
ABC versus GCB DLBCLs (FDR q < 0.001), with enrichment
scores even higher when comparing ABC versus mutant EZH2
DLBCLs (Figure S7A). Hence, EZH2 target genes, including
those with bivalent marks at the GC stage of development, are
expressed at relatively higher levels in ABC DLBCL cells, sug-
gesting that EZH2 does not play a key role in their regulation in
this form of lymphoma associated with the transformation of a
postgerminal center B cell.
If EZH2 is not critical for the suppression of bivalent genes that
drive proliferation once a cell exits the GC, then the biological
effects of EZH2 inhibition would be predicted to be significantly
different for ABC versus GCB lymphoma cells and ABC cells
might be predicted to be relatively insensitive to EZH2 inhibitors.
Therefore, we treated a panel of ABC and GCB DLBCL cell lines
with increasing concentrations of GSK343 or GSK503. Strikingly,
the drug concentrations required to inhibit 50% of growth (GI50)
for GCB lymphoma cell lines were in the 0.5–20 mM range, while,
for ABC cells, no significant inhibition of cell growth was
observed (p = 0.0004; Figures 7D and S7B–S7D). Exposure of
EZH2 WT GCB cells to a fixed dose of 10 mM GSK343 or
GSK503 led to 30%–75% reduction in viable cell number, while
EZH2 mutant GCB cells were inhibited 50%–99%, suggesting a
trend toward increased sensitivity. By contrast, this dose of drug
led to no killing of ABC lymphoma cells (p = 0.0001 versus GCB;
Figures 7E and S7E). EZH2 inhibitors completely demethylated
H3K27me3 in ABC-DLBCL cells, indicating that resistance is
biological and not due to failure of the drug to inhibit its target
(Figure S7F). Collectively, these data suggest that EZH2 inhibi-
tors may be useful for GCB DLBCL either with or without EZH2
mutations but are likely to be ineffective for ABC-type DLBCL.
DISCUSSION
In this manuscript, we show that EZH2 is a master regulator of
the GC B cell phenotype, a function that is aberrantly reinforced
by mutant EZH2 lymphoma disease alleles (Figure 7F). We find
that EZH2 mediates its effects in GC B cells by repressing target
genes involved in proliferation checkpoints (e.g., CDKN1A) and
exit from the GC and terminal differentiation (e.g., IRF4 and
PRDM1). For immunoglobulin affinity maturation to occur, GC
B cells must maintain their phenotype long enough to transit
repeated rounds of division and somatic hypermutation. Hence,
in the absence of EZH2 function, which is needed to support the
GC B cell phenotype, mice display defective immunoglobulin
affinity maturation. Normally, EZH2 levels decrease as B cells
exit the GC reaction, enabling expression of genes that mediate
terminal differentiation (Velichutina et al., 2010). However, in the
presence of somatically mutated EZH2, suppression of GC exit
genes and checkpoints persists, resulting in hyperplasia, and(F) Boxplot of gene expression level of bivalent, H3K4me3 monovalent, H3K27me
(G andH) GSEA of GCB cell-specific bivalent genes in (G)WT versusmutant EZH2
(I) Heat map of relative expression of GCB cell bivalent genes repressed in WT a
See also Figure S5.the presence of other oncogenic hits enables transformation to
GCB-type DLBCL (Figure 7F). An alternative route leading to
GCB-DLBCL could involve overexpression or aberrant mainte-
nance of WT EZH2. Indeed, the highest quartile WT EZH2-
expressing GCB-DLBCLs display a trend toward increased
repression of EZH2 targets and tend to cluster together with
EZH2 mutant patients (Figure S7G). The role of EZH2 in lym-
phomas is in large part to maintain or exaggerate (i.e., to hijack)
the same EZH2 transcriptional program that is also required for
development of normal GCs and immunoglobulin affinity matu-
ration. Hence, GC B cells exhibit both oncogene and nononco-
gene addiction to EZH2.
The actions of EZH2 appear linked in part to de novo formation
of bivalent chromatin domains, whereby genes marked by
H3K4me3 in naive follicular B cells acquire H3K27me3 in GC
B cells, concordant with upregulation of EZH2. In stem cells,
bivalent (H3K4me3/H3K27me3) domains are hypothesized to
maintain genes in a repressed but poised conformation, which
can be subsequently dynamically activated or repressed
according to lineage-specific differentiation programs (Bernstein
et al., 2006; Shin et al., 2012). GC B cells represent a potentially
unique situation where bivalent chromatin marks at specific
genes are gained during differentiation, while in ES and tissue
stem cell differentiation, they are lost. We however cannot
exclude that other cell types and tumors that may overexpress
EZH2 might also form bivalent domains at promoters. GC biva-
lent promoters are enriched in key gene sets involved in exit
from the GC, such as IRF4- and CD40-induced genes, and
genes upregulated in memory and plasma cells. As long as
EZH2 maintains H3K27me3 at these loci, these genes are
expressed at low levels, maintaining the GC phenotype. Repres-
sion of these genes is terminated as B cells exit the GC reaction
and are selected for terminal differentiation. By contrast, EZH2
mutants disrupt the equilibrium of bivalent domains, enabling
aberrant, persistent epigenetic silencing of genes, which in turn
allows the GC B cell phenotype to persist, facilitating lymphoid
transformation. Consistent with this hypothesis, we found that
bivalent domain genes are the most aberrantly repressed in
loci in EZH2 mutant DLBCL patient specimens. These data,
along with the recent identification of frequent loss-of-function
mutations in the histone methyltransferase protein MLL2 in
B cell lymphomas (Lohr et al., 2012; Morin et al., 2011), suggest
that the balance of H3K4me3 and H3K27me3 is disrupted and
represents a therapeutic target in lymphoid malignancies. Muta-
tions in MLL2 and EZH2 in lymphoma are not mutually exclusive
(Morin et al., 2011), suggesting these mutations may cooperate
to deregulate bivalent domains in GC B cells or that they also
have independent roles in lymphomagenesis.
EZH2 mutants may also mediate their actions through addi-
tional mechanisms. We and others have noted that H3K27
ChIP-seq profiles as well as gene expression profiles induced
by EZH2 inhibitors are variable between cell lines (McCabe
et al., 2012b), suggesting that hyperactive EZH2 molecule might
lead to epigenetic instability and stochastic aberrant epigenetic3 monovalent, and promoters not exhibiting either of these marks in GCB cells.
BCL1 cells and (H) GCB-DLBCL patient sampleswithWT versusmutant EZH2.
nd mutant EZH2 GCB-DLBCL patient samples.
Cancer Cell 23, 677–692, May 13, 2013 ª2013 Elsevier Inc. 687
AC
E
G
H
D
F
B
Figure 6. EZH2 Cooperates with BCL2 to Generate Germinal Center-Derived Lymphomas
(A) Bone marrow transplantation was performed using VavP-Bcl2 transgenic donor mice.
(B) Representative pictures of spleens from mice sacrificed 111 days after transplantation and quantification of the spleen weight (n = 10 per group).
(C) Immunoblotting from whole cell lysates from splenocytes of transplanted mice.
(D) Quantification of the liver weight of transplanted mice (n = 10 per group).
(E) Splenic tissue from transplanted mice was stained with hematoxylin and eosin (H&E), B220, and EZH2.
(F) Tumor clonality analysis by RT-PCR performed in B220+ sorted splenocytes. Sample lanes separated by thin white lines were run on the same gel but were
noncontiguous.
(G) Dose reduction plot for Obatoclax and ABT737 at GI90 after exposure of cells to increasing concentrations of GSK343 for 6 days. Data represent mean of
triplicate experiments.
(legend continued on next page)
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Role of EZH2 in B Cell Lymphomassilencing of different gene sets. On the other hand, variability
may be due to the fact that cell lines are genetically quite diverse
and, under the stress of continuous passage in vitro, tend to drift
apart epigenetically. This has been demonstrated in the case of
cytosine methylation profiles, which differ considerably between
lymphoma cell lines and primary lymphoma specimens (De et al.,
2013). By contrast, primary human DLBCL specimens with
mutant EZH2 showed a robust signature, consisting of greater
repression of EZH2 target genes, including bivalent domains
and with similarity to the EZH2 mutant signature induced in the
isogenic BCL1 experimental model. Moreover, analysis of indi-
vidual DLBCL cell lines after exposure to GSK343 showed upre-
gulation of GC B cell EZH2 targets, including bivalent genes as
well as phenotypic effects consistent with derepression of GC
B cell EZH2 target genes. Notably, these studies underline that
EZH2-mediated epigenetic effects are reversible in lymphomas,
which is consistent with data in the prostate cancer field also
showing that suppression of EZH2 can result in reactivation of
genes with tumor-suppressing activity (Taniguchi et al., 2012;
Yu et al., 2007).
Expression ofmutant EZH2 alone inGCB cells was insufficient
to induce development of DLBCL. In this way, EZH2 mutation
appears analogous to many of the somatic mutations in acute
myeloid leukemia (AML), which induce a myeloproliferative
phenotype when expressed in murine hematopoietic stem cells
but, when expressed together, cooperate to form AML (Shih
et al., 2012). Mutant EZH2 induces a lymphoproliferative pheno-
type with expansion of the proliferative GC B cell compartment.
Constitutive expression of the GC B cell oncoproteins BCL6 and
BCL2 also manifest GC hyperplasia and a partially penetrant GC
B cell lymphoma phenotype (Cattoretti et al., 2005; Egle et al.,
2004). Hence, even though normal GC B cells exhibit features
of partially transformed cells, such as suppression of prolifera-
tive checkpoints and attenuated DNA damage response, multi-
ple oncogenic hits are still required for overt lymphomagenesis.
This concept is supported by mutational profiling studies,
revealingmultiple concurrent somatic mutations in DLBCL spec-
imens (Lohr et al., 2012; Morin et al., 2011), as well as our trans-
plantation studies, demonstrating cooperation between mutant
EZH2 and BCL2 in accelerating lymphomagenesis in mice.
Knowledge of the genetic composition of lymphomas and how
these cooperate to transform B cells affords the opportunity to
rationally design combinatorial therapies. The enhanced antilym-
phoma activities of GSK343 and GSK503 in combination with
anti-BCL2 therapies support this notion and point toward design
of clinical trials geared toward the underlying biology of DLBCL
and a reduced reliance on relatively nonspecific cytotoxic
chemotherapy.
While previous reports have focused on the role of EZH2
inhibitors against mutant-EZH2 DLBCL (Knutson et al., 2012;
McCabe et al., 2012b; Qi et al., 2012), our data indicate that
EZH2 is a relevant target beyond those tumors. We find that
GCB-type DLBCLs are dependent on wild-type EZH2 for their(H) Area under the curve (AUC) of the tumor growth curves for 20 days in SUD
(2 mg/kg/day, n = 8 in SUDHL4 and n = 7 in SUDHL6), GSK503 (150 mg/kg/day,
GSK503 (n = 8 in SUDHL4 and n = 7 in SUDHL6).
The p values were calculated by t test. Values in (B)–(D) and (H) are mean ± SEM
See also Figure S6.proliferation and survival, regardless of somatic mutation,
although response to EZH2 inhibitors is slightly delayed as
compared to mutant EZH2 DLBCL cells. This finding is in agree-
ment with the absolute requirement of normal GC B cells for
EZH2 and indicates that EZH2 is a lineage factor to which
GC-type DLBCLs are addicted (Figure 7F). By contrast,
ABC-DLBCLs do not require EZH2 to maintain their proliferation
and survival. Indeed, the target genes repressed by EZH2
consist of many of same genes that define the ABC-DLBCL sub-
type. These data provide a mechanism by which increased
EZH2-mediated repression of target genes can impair B cell
differentiation and demonstrate that therapeutic targeting of
EZH2 in GCB DLBCLs can induce differentiation and abrogate
proliferation of GCB-DLBCLs with mutant or wild-type EZH2.
We thus provide the basis for the expanded clinical translation
of EZH2 inhibitors for the treatment of GCB-type DLBCLs.
Clinical studies with pharmacologic EZH2 inhibitors will deter-
mine if this approach can improve outcomes for lymphoma
patients. Although many GCB-type DLBCLs can be cured with
combination chemoimmunotherapy regimens, these involve
the use of toxic drugs that carry a lifelong risk of developing
second malignancies. The current standard therapy for B cell
lymphomas (RCHOP) wipes out the entire bone marrow of
patients, and the B cell lineage is completely eradicated for
months by rituximab (anti-CD20 antibody). In comparison, the
transient suppression of high-affinity antibody formation by
EZH2 inhibitors seems less likely to be clinically significant. By
targeting the oncoproteins that drive and define the GCB DLBCL
phenotype, it may be possible to reduce our reliance on cyto-
toxic drugs to eradicate this disease.
EXPERIMENTAL PROCEDURES
Amore detailed description of the experimental procedures and reagents used
in this study can be found in the Supplemental Experimental Procedures.
Generation of Conditional Ezh2Y641N Knockin Mice
Ezh2Y641N mice were generated by Frt-mediated targeting of Ezh2Y641N
into the ColA1 locus. The strategy for FLPe-mediated recombination (shown
in Figure S2) was done as described previously (Beard et al., 2006). Briefly,
homologous recombination was used to place an frt-hygro-pA cassette
downstream of the ColA1 locus. Ezh2Y641N complementary DNA (cDNA)
was then targeted to the modified locus by coelectroporation of a pgkATGfrt
vector carrying Ezh2Y641N and an FLPe transient expression vector. This
pgkATGfrt contains the PGK promoter, an ATG initiation codon, an frt site,
and a CAG promoter, driving the expression of Ezh2Y641N. Interspersed
between the CAG promoter and Ezh2Y641N cDNA is a lox-stop-lox (LSL)
cassette, ensuring that Ezh2Y641N is only expressed in the presence of
cre-mediated excision of the LSL cassette. Interstrand intrachromosomal
recombination at the frt sites results in loss of the PGKneopA cassette and
insertion of Ezh2Y641N and pgkATG cassette to restore and confer hygrom-
ycin resistance. The integration site is located 500 bp downstream of the
30 UTR of the ColA1 locus. This left the coding portion and 30 UTR transcrip-
tional control region of the ColA1 gene intact. V6.5 ES cells were electropo-
rated with this homologous targeting construct, and stable G418 clones
were derived.HL4 and SUDHL6 xenografted mice treated with vehicle (n = 7), Obatoclax
n = 8 in SUDHL4 and n = 7 in SUDHL6), or the combination of Obatoclax and
. t test, *p < 0.05, **p < 0.01, ***p < 0.001. BM, bone marrow.
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Figure 7. EZH2 Targeted Therapy Preferentially Affects GCB but Not ABC DLBCL Cells
(A) Heat map of relative expression of GCB-specific H3K27me3 target genes repressed in mutant EZH2 GCB-DLBCL patient samples.
(B and C) GSEA in ABC-DLBCL versus WT EZH2 GCB-DLBCL (B) and mutant EZH2 GCB-DLBCL (C).
(D and E) Four ABC-DLBCL (HBL-1, Ly3, U2932, and TMD8) and nine GCB-DLBCL cell lines (five WT EZH2: Ly7, Ly19, Farage, Ly18, SUDHL5 and four mutant
EZH2: Pfeiffer, WSU-DLCL2, SUDHL4, SUDHL6) were exposed to increasing concentrations of GSK343 and GSK669 for 6 days. (D) GI50 of GSK343 relative to
GSK669. (E) Cell viability at 10 mM GSK. Data are mean with 95% confidence interval for duplicate.
(F) When naive B cells are activated, EZH2 expression is highly induced. EZH2 is required for GC formation and Ig affinity maturation. EZH2 levels decrease as B
cells exit the GC reaction, enabling expression of genes that mediate terminal differentiation (e.g., IRF4, PRDM1, and NF-kB). B cells in this ‘‘exiting’’ phase, such
(legend continued on next page)
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The Research Animal Resource Center of the Weill Cornell Medical College
approved all mouse procedures. Conditional Ezh2 knockout mice (loxP-
flanked EZH2 allele, EZH2fl/fl) were a generous gift of Dr. Alexander Tarakhov-
sky, The Rockefeller University (Su et al., 2003). By crossing Ezh2fl/fl with the
transgenic Cg1cre strain (The Jackson Laboratory, 010611), we generated
heterozygous mice, which were crossed to yield Ezh2/ mice. As control
group, we used Ezh2fl/fl Cg1cre-negative littermates. Ezh2Y641N transgenic
mice were crossed with Cg1cre strain. The Cg1cre-negative littermates
were used as control group. Conditional Ezh2 knockout and Ezh2Y641N knockin
mice were used for assessment of the germinal center formation, which were
induced with SRBC or NP-KLH.
DLBCL Patient Samples
Patient-deidentified leftover tissues were obtained at diagnosis from 69
patients with de novo DLBCL in Vancouver at the British Columbia Cancer
Agency. Cases were selected on the basis of the presence of at least 80%
of the neoplastic cells within the tumor section. The use of human tissue
was approved by the research ethics board of the Vancouver Cancer
Center/University of British Columbia and the Weill Cornell Medical Center.
For additional information, see Table S6 and Supplemental Experimental
Procedures.
ChIP-seq and mRNA-seq Library Preparation and Illumina
Sequencing Processing
ChIP-seq and RNA-seq libraries were prepared using the Illumina ChIP-Seq
and TruSeq RNA sample kits, respectively, according to the manufacturer.
Libraries were validated using the Agilent Technologies 2100 Bioanalyzer
and Quant-iT dsDNA HS Assay (Life Technologies) and 8–10 pM sequenced
on HiSeq2000 sequencer as follows: ChIP-seq, 1 3 50 and messenger RNA
sequencing (mRNA-seq), 2 3 50. RNA-seq data were aligned to transcripts
using TopHat (Trapnell et al., 2009), gene expression quantified in fragments
per kilobase of exon per million fragments mapped (Mortazavi et al., 2008),
and differentially expressed genes identified. ChIP-seq experiments from
human B cells, human cell lines, and murine cells were aligned to the hg18,
hg19, and mm9 genome, respectively, using ELAND. H3K4me3 ChIP-seq
reads were called into peaks using the ChIPseeqer framework (p < 1015
and fold-change threshold 2) (Giannopoulou and Elemento, 2011), and
H3K27me3 and EZH2 ChIP-seq reads were quantified in 1 kb bins genome-
wide, identifying regions of enrichment as consecutive bins with read counts
greater than 1 SD of the genome-wide mean. Data analysis is described in
Supplemental Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession numbers for the ChIP-seq, RNA-
seq, and the expression microarray data reported in this paper are
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Supplemental Information includes seven figures, six tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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